Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
GLP-1RA

New US Ozempic 3mL Pen Offering for Maintenance Dosing

Here is a brief preview of this blast: According to Drugs@FDA, the Ozempic US label has been updated to reflect a new 3mL pen offering for a maintenance dose of 1mg. The new pen has a different NDC (0169-4130-13) and dials 4 doses of 1mg each. The new pen represents a total strength of 4 mg/3 mL and harmonizes the maximum pen strength offered in Europe. Below, FENIX provides thoughts on this new pen offering including potential reasons around manufacturing efficiencies.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.